[Form 4] CAMP4 Therapeutics Corporation Insider Trading Activity

Rhea-AI Filing Summary

Camp4 Therapeutics officer purchased 6,060 shares in a private placement at $1.65 per share. Yuri Maricich, identified as Chief Medical Officer and a reporting person, acquired the shares pursuant to a Securities Purchase Agreement dated September 9, 2025, with the transaction dated September 11, 2025.

The purchase was part of a private placement involving institutional investors and certain directors, employees, and consultants. Following the purchase, the reporting person directly owns 6,060 shares.

Positive

• Officer purchase disclosed: Chief Medical Officer Yuri Maricich directly acquired 6,060 shares, aligning management interests with shareholders.

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider purchase of 6,060 shares at $1.65 signals modest insider alignment but is not material alone.

The Form 4 shows a direct purchase by the Chief Medical Officer in a private placement priced at $1.65 per share. The transaction size—6,060 shares—is small relative to typical market-capitalization impacts and no derivative holdings or dispositions were reported. This disclosure provides a limited positive governance signal that an officer participated in the financing, without indicating a material change to ownership or control.

Corporate Governance Expert

TL;DR: Filing documents routine insider participation in issuer financing; compliance and transparency are intact.

The Form 4 is properly executed and signed by an attorney-in-fact, showing compliance with Section 16 reporting. The participation in a broader private placement that included institutional and insider participants is disclosed. There are no indicated conflicts, indirect ownership claims, or amendments noted, so the filing meets standard disclosure expectations for insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maricich Yuri

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		P		6,060	A	$1.65(1)	6,060	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.

Remarks:

	/s/ Josh Mandel-Brehm, as Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CAMP report on the Form 4?

The Form 4 reports that Chief Medical Officer Yuri Maricich directly purchased 6,060 shares of Camp4 Therapeutics at $1.65 per share in a private placement on 09/11/2025.

Was the purchase part of a larger financing for CAMP (CAMP)?

Yes. The filing states the acquisition was made pursuant to a Securities Purchase Agreement dated 09/09/2025 that involved institutional investors and certain directors, employees, and consultants.

How many shares does the reporting person own after the transaction?

Following the reported transaction, the reporting person directly beneficially owns 6,060 shares.

Did the filing report any derivative transactions or dispositions?

No. Table II (derivative securities) contains no reported entries and Table I shows only the single acquisition with no dispositions.

Who signed the Form 4 filing for the reporting person?

The filing is signed by /s/ Josh Mandel-Brehm, as Attorney-in-Fact with the signature date of 09/11/2025.